- Home
- IMMP vs DHY Comparison
IMMP vs DHY Comparison
Compare IMMP & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- DHY
- Stock Information
- Founded
- IMMP 1987
- DHY 1998
- Country
- IMMP Australia
- DHY United States
- Employees
- IMMP N/A
- DHY N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- DHY Finance/Investors Services
- Sector
- IMMP Health Care
- DHY Finance
- Exchange
- IMMP Nasdaq
- DHY Nasdaq
- Market Cap
- IMMP 256.1M
- DHY 216.5M
- IPO Year
- IMMP N/A
- DHY N/A
- Fundamental
- Price
- IMMP $1.90
- DHY $2.06
- Analyst Decision
- IMMP Buy
- DHY
- Analyst Count
- IMMP 1
- DHY 0
- Target Price
- IMMP $7.00
- DHY N/A
- AVG Volume (30 Days)
- IMMP 128.2K
- DHY 569.1K
- Earning Date
- IMMP 02-22-2026
- DHY 01-01-0001
- Dividend Yield
- IMMP N/A
- DHY 9.10%
- EPS Growth
- IMMP N/A
- DHY N/A
- EPS
- IMMP N/A
- DHY N/A
- Revenue
- IMMP $3,306,742.00
- DHY N/A
- Revenue This Year
- IMMP N/A
- DHY N/A
- Revenue Next Year
- IMMP N/A
- DHY N/A
- P/E Ratio
- IMMP N/A
- DHY N/A
- Revenue Growth
- IMMP 31.28
- DHY N/A
- 52 Week Low
- IMMP $1.32
- DHY $1.77
- 52 Week High
- IMMP $2.71
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- IMMP 56.87
- DHY 54.62
- Support Level
- IMMP $1.68
- DHY $1.99
- Resistance Level
- IMMP $1.95
- DHY $2.07
- Average True Range (ATR)
- IMMP 0.09
- DHY 0.02
- MACD
- IMMP 0.01
- DHY 0.00
- Stochastic Oscillator
- IMMP 82.14
- DHY 87.50
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.